Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Study of Lunresertib Alone or in Combination With RP-3500 or Zedoresertib (Debio 0123) in Patients With Advanced Solid Tumors (MYTHIC)

16 november 2026 bijgewerkt door: Debiopharm International SA

Fase 1-studie van de veiligheid, farmacokinetiek, farmacodynamiek en voorlopige klinische activiteit van RP-6306 alleen of in combinatie met RP-3500 bij patiënten met vergevorderde solide tumoren

The primary purpose of this study is to assess the safety and tolerability of lunresertib alone and in combination with RP-3500 or in combination with zedoresertib in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) and assess preliminary anti-tumor activity.

Studie Overzicht

Gedetailleerde beschrijving

Phase 1/1b, multi-center, open-label, dose-escalation study to:

  • Evaluate the safety profile and MTD of lunresertib alone and in combination with RP-3500 or in combination with zedoresertib when administered orally to establish the recommended Phase 2 dose and schedule
  • Characterize the PK and pharmacodynamics of lunresertib alone and in combination with RP-3500 or in combination with zedoresertib
  • Assess preliminary anti-tumor activity associated with lunresertib alone and in combination with RP-3500 or in combination with zedoresertib

This study was previously posted by Repare Therapeutics. In September 2025, sponsorship of the trial was transferred to Debiopharm International S.A

Expanded Access Status: There is no expanded access program available for the investigational products in this study at this time.

Studietype

Ingrijpend

Inschrijving (Geschat)

464

Fase

  • Fase 1

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

    • Ontario
      • Toronto, Ontario, Canada, M5G 1X8
        • Voltooid
        • #2002, The Hospital for Sick Children
      • Toronto, Ontario, Canada, M5G 2C1
        • Werving
        • #2001, Princess Margaret Cancer Centre
    • Quebec
      • Montreal, Quebec, Canada, H4A 3J1
        • Voltooid
        • #2003, The Research Institute of the McGill University Health Centre
      • Copenhagen, Denemarken
        • Werving
        • #4001, Rigshospitalet - Blegdamsvej
      • Madrid, Spanje, 28027
        • Nog niet aan het werven
        • Clinica Universidad de Navarra
      • Madrid, Spanje, 28050
        • Werving
        • Hospital Universitario HM Sanchinarro
      • Madrid, Spanje, 28040
        • Werving
        • START Madrid. Hospital Fundación Jimenez Diaz
      • Navarra, Spanje, 31008
        • Nog niet aan het werven
        • Clinica Universidad de Navarra
      • London, Verenigd Koninkrijk, W1G 6AD
        • Werving
        • #3003, Sarah Cannon Research Institute
    • California
      • Los Angeles, California, Verenigde Staten, 90095
        • Voltooid
        • # 1019, UCLA, Westwood Cancer Center
      • San Francisco, California, Verenigde Staten, 94158
        • Werving
        • #1025, University of California San Francisco
    • Connecticut
      • New Haven, Connecticut, Verenigde Staten, 06520
        • Werving
        • #1012, Yale
    • Florida
      • Jacksonville, Florida, Verenigde Staten, 32224
        • Werving
        • #1017, Mayo Clinic
    • Massachusetts
      • Boston, Massachusetts, Verenigde Staten, 02215
        • Werving
        • #1002, Dana Farber Cancer Institute
    • Michigan
      • Grand Rapids, Michigan, Verenigde Staten, 49503
        • Werving
        • #1023, START Midwest
    • Minnesota
      • Rochester, Minnesota, Verenigde Staten, 55902
        • Werving
        • #1016, Mayo Clinic
    • Missouri
      • St Louis, Missouri, Verenigde Staten, 63130
        • Werving
        • #1011, Washington University
    • New York
      • New Hyde Park, New York, Verenigde Staten, 11042
        • Werving
        • #1032, Northwell Health Cancer Institute
      • New York, New York, Verenigde Staten, 10065
        • Werving
        • #1004, Memorial Sloan Kettering Cancer Institute
      • New York, New York, Verenigde Staten, 10032
        • Voltooid
        • #1008, Columbia University
    • Pennsylvania
      • Philadelphia, Pennsylvania, Verenigde Staten, 19104
        • Voltooid
        • #1010, University of Pennsylvania
    • Rhode Island
      • Providence, Rhode Island, Verenigde Staten, 02903
        • Werving
        • #1007, Rhode Island Hospital
      • Providence, Rhode Island, Verenigde Staten, 02903
        • Werving
        • #1030, Women & Infants Hospital of Rhode Island
    • Texas
      • Houston, Texas, Verenigde Staten, 77030
        • Werving
        • #1001, The University of Texas M.D. Anderson Cancer Center
    • Utah
      • Salt Lake City, Utah, Verenigde Staten, 84112
        • Werving
        • #1013, The University of Utah
    • Virginia
      • Charlottesville, Virginia, Verenigde Staten, 22903
        • Werving
        • #1027, University of Virginia

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

12 jaar en ouder (Kind, Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Male or female and ≥12 years-of-age at the time of informed consent.
  • Lansky performance status ≥50% for patients ≤16 years of age, or ECOG score of 0, 1, (or 2 for module 1) for patients >16 years of age.
  • Locally advanced or metastatic resistant or refractory solid tumors.
  • Patients <18 years of age must weigh at least 40 kg.
  • Submission of available tumor tissue at screening or willingness to have a biopsy performed if safe and feasible
  • Next generation sequencing (NGS) report obtained in a CLIA-certified or equivalent laboratory demonstrating eligible tumor biomarker.
  • CCNE1 amplification (non-equivocal) as determined by either a tumor or plasma NGS test, or FISH
  • FBXW7 deleterious mutations identified by either a tumor or plasma NGS test
  • PPP2R1A deleterious mutations identified by either a tumor or plasma NGS test
  • Measurable disease as per RECIST v1.1. For certain modules, patients with prostate cancer or ovarian cancer that have non-measurable disease but have elevated tumor markers (PSA or CA-125, respectively) can also be eligible
  • Ability to swallow and retain oral medications.
  • Acceptable hematologic and organ function at screening.
  • Negative pregnancy test (serum) for women of childbearing potential (WOCBP) at Screening.
  • Resolution of all toxicities of prior therapy or surgical procedures.
  • Any prior radiation must have been completed at least 7 days prior to the start of study drugs, and patients must have recovered from any acute adverse effects prior to the start of study treatment.

Exclusion Criteria:

  • Chemotherapy or small molecule antineoplastic agent given within 21 days or <5 half-lives, whichever is shorter, prior to first dose of study drug.
  • History or current condition, therapy, or laboratory abnormality that might confound the study results or interfere with the patient's participation for the full duration of the study treatment.
  • Patients who are pregnant or breastfeeding.
  • Life-threatening illness, medical condition, active uncontrolled infection, or organ system dysfunction or other reasons which, in the investigator's opinion, could compromise the participating patient's safety.
  • Major surgery within 4 weeks prior to first dose of lunresertib.
  • Uncontrolled, symptomatic brain metastases.
  • Uncontrolled hypertension.
  • Certain prior anti-cancer therapy
  • Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol and/or follow-up procedures outlined in the protocol.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Niet-gerandomiseerd
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Phase 1: Lunresertib Single-Agent, Dose Escalation and Food-effect Study

Patients receive lunresertib orally until disease progression, unacceptable toxicity, or investigator/patient decision. Dose escalation will proceed until a maximum tolerated dose is identified.

Oral PKMYT1 Inhibitor

Experimenteel: Phase 1: Lunresertib in combination with RP-3500, Dose Escalation Study

Patients receive lunresertib with RP-3500 orally until disease progression, unacceptable toxicity, or investigator/patient decision. Dose escalation will proceed until a maximum tolerated dose is identified.

Oral PKMYT1 Inhibitor

Oral ATR Inhibitor

Experimenteel: Phase 1: Lunresertib in combination with Zedoresertib, Dose Escalation Study

Patients receive lunresertib with zedoresertib orally until disease progression, unacceptable toxicity, or investigator/patient decision. Dose escalation will proceed until a maximum tolerated dose is identified.

Oral PKMYT1 Inhibitor

Oral WEE1 Inhibitor

Andere namen:
  • Debio 0123

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Safety and Tolerability of lunresertib either in monotherapy or in combination with RP-3500 or with Zedoresertib in patients with eligible advanced solid tumors
Tijdsspanne: Up to 90 days after last administration of study intervention

Assessed by treatment-emergent adverse events (TEAEs), physical examinations (PEs), safety laboratory assessments, electrocardiograms (ECGs), and vital sign measurements

Up to 90 days after last administration of study intervention
To define the MTD of lunresertib monotherapy, and determine a recommended Phase 2 dose (RP2D) and preferred schedule
Tijdsspanne: Up to 90 days after last administration of study intervention

Assessed by the incidence of Dose-limiting toxicities (DLTs) and the incidence and severity of cumulative safety data

Up to 90 days after last administration of study intervention
To define the MTD of lunresertib in combination with RP-3500 or in combination with Zedoresertib, and determine a recommended Phase 2 dose (RP2D) and preferred schedule
Tijdsspanne: Up to 90 days after last administration of study intervention

Assessed by the incidence of dose-limiting toxicities (DLTs) and the incidence and severity of cumulative safety data

Up to 90 days after last administration of study intervention
The relative bioavailability of lunresertib capsule formulation as compared to lunresertib tablet formulation in the fasted state
Tijdsspanne: Time 0 (time of dosing) to 72 hours post-dose for each treatment condition

Assessed by the plasma concentrations of lunresertib with calculation of pharmacokinetic (PK) parameters including maximum observed plasma concentration (Cmax), time to maximum observed plasma concentration (Tmax), area under the plasma concentration-time curve (AUC) , for both formulations in the fasted state.

Time 0 (time of dosing) to 72 hours post-dose for each treatment condition
The effect of food on the PK of tablet formulation of lunresertib when administered in fed conditions compared to administration under fasted conditions
Tijdsspanne: Time 0 (time of dosing) to 72 hours post-dose for each treatment condition

Assessed by the plasma concentrations of lunresertib with calculation of the ratio of PK parameters (e.g., Cmax and AUC) between the tablet formulation under fasted and fed state.

Time 0 (time of dosing) to 72 hours post-dose for each treatment condition
To assess the safety and tolerability of lunresertib tablets in combination with RP-3500, confirm the MTD of lunresertib tablets in combination with RP-3500, and determine a RP2D and preferred schedule
Tijdsspanne: Up to 90 days after last administration of study intervention

Assessed by DLTs, TEAEs, safety laboratory assessments, the incidence of DLTs and the incidence and severity of cumulative safety data

Up to 90 days after last administration of study intervention

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
The plasma concentrations of lunresertib monotherapy (capsule formulation) in the fasted and fed states
Tijdsspanne: Up to 90 days after last administration of study intervention

Assessed by the plasma concentrations of lunresertib with calculation of maximum observed plasma concentration (Cmax), time to maximum observed plasma concentration (Tmax), minimum observed plasma concentration (Cmin), area under the plasma concentration-time curve (AUC), elimination half-life (t1/2), and other parameters as appropriate

Up to 90 days after last administration of study intervention
To assess the relationship between pharmacodynamic biomarkers and PK of lunresertib at different dose levels and/or schedules
Tijdsspanne: Up to 90 days after last administration of study intervention

Assessed by evaluation of biomarkers in pre- and on-treatment biopsies, and circulating tumor DNA (ctDNA) dynamics during treatment

Up to 90 days after last administration of study intervention
The plasma concentrations of lunresertib and RP-3500 when dosed in combination
Tijdsspanne: Up to 90 days after last administration of study intervention

Assessed by the plasma concentrations of lunresertib and RP-3500 with calculation of maximum observed plasma concentration (Cmax), time to maximum observed plasma concentration (Tmax), minimum observed plasma concentration (Cmin), area under the plasma concentration-time curve (AUC), elimination half-life (t1/2), and other parameters as appropriate for each analyte

Up to 90 days after last administration of study intervention
To assess preliminary anti-tumor activity achieved with lunresertib monotherapy, lunresertib in combination with RP-3500 or lunresertib in combination with Zedoresertib
Tijdsspanne: Through Study Completion, an average of 1 year

Measured by best percent change in tumor size from baseline, objective response rate (ORR), overall response rate, tumor marker response, duration of response (DOR), clinical benefit rate (CBR), progression-free survival (PFS).

Through Study Completion, an average of 1 year
To assess the safety and anti-tumor effects of lunresertib capsule + RP-3500
Tijdsspanne: Through Study Completion, an average of 1 year

As measure by TEAEs, safety laboratory assessments, Best percent change in tumor size from baseline, ORR, overall response rate, DOR, CBR, tumor marker response, PFS

Through Study Completion, an average of 1 year
To further characterize the PK of lunresertib tablets and assess preliminary anti-tumor
Tijdsspanne: Through Study Completion, an average of 1 year

Measured by Plasma concentrations of lunresertib with calculation of Cmax, Tmax, AUC, elimination t1/2, and other PK parameters as appropriate, Best percent change in tumor size from baseline, ORR, overall response rate, DOR, CBR, tumor marker response, PFS

Through Study Completion, an average of 1 year

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

30 april 2021

Primaire voltooiing (Geschat)

1 december 2027

Studie voltooiing (Geschat)

1 juni 2028

Studieregistratiedata

Eerst ingediend

9 april 2021

Eerst ingediend dat voldeed aan de QC-criteria

19 april 2021

Eerst geplaatst (Werkelijk)

22 april 2021

Updates van studierecords

Laatste update geplaatst (Werkelijk)

17 november 2026

Laatste update ingediend die voldeed aan QC-criteria

16 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • Debio 0123-106
  • RP-6306-01 (Andere identificatie: Repare Therapeutics)

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren